{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:21:05Z","timestamp":1794543665045,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Edmond Pharma Srl","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12931-019-1078-y","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T14:02:27Z","timestamp":1558965747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Efficacy and safety profile of mucolytic\/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5040","authenticated-orcid":false,"given":"Paola","family":"Rogliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermanno","family":"Puxeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"1078_CR1","unstructured":"GOLD: Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD \u2013 2019 Report. Available from \n                    https:\/\/goldcopd.org\/wp-content\/uploads\/2018\/11\/GOLD-2019-v1.5-FINAL-04Nov2018_WMS.pdf\n                    \n                  . Last accessed March 11, 2019. 2019."},{"key":"1078_CR2","doi-asserted-by":"crossref","unstructured":"Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015:CD001287.","DOI":"10.1002\/14651858.CD001287.pub5"},{"key":"1078_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1183\/16000617.00002215","volume":"24","author":"M Cazzola","year":"2015","unstructured":"Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Gabriella Matera M. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24:451\u201361.","journal-title":"Eur Respir Rev"},{"key":"1078_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.rmed.2018.12.014","volume":"147","author":"A Papi","year":"2019","unstructured":"Papi A, Zheng J, Criner GJ, Fabbri LM, Calverley PMA. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post-hoc analysis of the PANTHEON study. Respir Med. 2019;147:37\u201343.","journal-title":"Respir Med"},{"key":"1078_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1080\/15412555.2017.1347918","volume":"14","author":"M Cazzola","year":"2017","unstructured":"Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017;14:552\u201363.","journal-title":"COPD"},{"issue":"4","key":"1078_CR6","doi-asserted-by":"publisher","first-page":"1700711","DOI":"10.1183\/13993003.00711-2017","volume":"50","author":"Roberto W. Dal Negro","year":"2017","unstructured":"Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, Pozzi E, Calverley PMA, Group R, Study R. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017;50.","journal-title":"European Respiratory Journal"},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","volume":"2","author":"JP Zheng","year":"2014","unstructured":"Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187\u201394.","journal-title":"Lancet Respir Med"},{"key":"1078_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1378\/chest.12-2357","volume":"144","author":"HN Tse","year":"2013","unstructured":"Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, Loo CK, Chan MH. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144:106\u201318.","journal-title":"Chest"},{"key":"1078_CR9","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","volume":"371","author":"JP Zheng","year":"2008","unstructured":"Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ, Wang C, Chen BY, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet. 2008;371:2013\u20138.","journal-title":"Lancet"},{"key":"1078_CR10","first-page":"143","volume":"30","author":"M Moretti","year":"2004","unstructured":"Moretti M, Bottrighi P, Dallari R, Da Porto R, Dolcetti A, Grandi P, Garuti G, Guffanti E, Roversi P, De Gugliemo M, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Exp Clin Res. 2004;30:143\u201352.","journal-title":"Drugs Exp Clin Res"},{"key":"1078_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"1078_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1078_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.pupt.2017.11.009","volume":"48","author":"M Cazzola","year":"2018","unstructured":"Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Impact of erdosteine on chronic bronchitis and COPD: a meta-analysis. Pulm Pharmacol Ther. 2018;48:185\u201394.","journal-title":"Pulm Pharmacol Ther"},{"key":"1078_CR14","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2147\/COPD.S140603","volume":"12","author":"Z Zeng","year":"2017","unstructured":"Zeng Z, Yang D, Huang X, Xiao Z. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:2277\u201383.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1078_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.hrtlng.2016.12.004","volume":"46","author":"K Fowdar","year":"2017","unstructured":"Fowdar K, Chen H, He Z, Zhang J, Zhong X, Zhang J, Li M, Bai J. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: a meta-analysis and systematic review. Heart Lung. 2017;46:120\u20138.","journal-title":"Heart Lung"},{"key":"1078_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest. 2016;149:1181\u201396.","journal-title":"Chest"},{"key":"1078_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"1078_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13643-016-0368-4","volume":"5","author":"H Pedder","year":"2016","unstructured":"Pedder H, Sarri G, Keeney E, Nunes V, Dias S. Data extraction for complex meta-analysis (DECiMAL) guide. Syst Rev. 2016;5:212.","journal-title":"Syst Rev"},{"key":"1078_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pupt.2017.06.002","volume":"45","author":"L Calzetta","year":"2017","unstructured":"Calzetta L, Matera MG, Braido F, Contoli M, Corsico A, Di Marco F, Santus P, Scichilone N, Cazzola M, Rogliani P. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017;45:148\u201358.","journal-title":"Pulm Pharmacol Ther"},{"key":"1078_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-4-17","volume":"4","author":"JP Guevara","year":"2004","unstructured":"Guevara JP, Berlin JA, Wolf FM. Meta-analytic methods for pooling rates when follow-up duration varies: a case study. BMC Med Res Methodol. 2004;4:17.","journal-title":"BMC Med Res Methodol"},{"key":"1078_CR21","unstructured":"Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from \n                    https:\/\/handbook-5-1.cochrane.org\/chapter_9\/9_6_4_meta_regression.htm\n                    \n                  . The Cochrane Collaboration 2011, 9.6.4 Meta-regression."},{"key":"1078_CR22","doi-asserted-by":"crossref","unstructured":"Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG. Impact of doxofylline in COPD: a pair-wise meta-analysis. Pulm Pharmacol Ther. 2018.","DOI":"10.1183\/13993003.congress-2018.PA616"},{"issue":"148","key":"1078_CR23","doi-asserted-by":"publisher","first-page":"180010","DOI":"10.1183\/16000617.0010-2018","volume":"27","author":"Mario Cazzola","year":"2018","unstructured":"Cazzola M, Calzetta L, Barnes PJ, Criner GJ, Martinez FJ, Papi A, Gabriella Matera M. Efficacy and safety profile of xanthines in COPD: a network meta-analysis. Eur Respir Rev. 2018;27.","journal-title":"European Respiratory Review"},{"key":"1078_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2017.06.020","volume":"129","author":"L Calzetta","year":"2017","unstructured":"Calzetta L, Ora J, Cavalli F, Rogliani P, O'Donnell DE, Cazzola M. Impact of LABA\/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysis. Respir Med. 2017;129:189\u201398.","journal-title":"Respir Med"},{"key":"1078_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1741-7015-9-79","volume":"9","author":"T Li","year":"2011","unstructured":"Li T, Puhan MA, Vedula SS, Singh S, Dickersin K. Ad hoc network meta-analysis methods meeting working G: network meta-analysis-highly attractive but more methodological research is needed. BMC Med. 2011;9:79.","journal-title":"BMC Med"},{"key":"1078_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/16000617.0043-2016","volume":"0","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Gabriella Matera M. LABA\/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2016;0:1\u201311. \n                    https:\/\/doi.org\/10.1183\/16000617.0043-2016\n                    \n                  .","journal-title":"Eur Respir Rev"},{"issue":"1","key":"1078_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/2042098616667304","volume":"8","author":"Mario Cazzola","year":"2016","unstructured":"Cazzola M, Calzetta L, Rogliani P, Matera MG. Tiotropium formulations and safety: a network meta-analysis. Therapeutic Advances in Drug Safety. 2016:2042098616667304. \n                    https:\/\/doi.org\/10.1177\/2042098616667304\n                    \n                  .","journal-title":"Therapeutic Advances in Drug Safety"},{"key":"1078_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00151829-200605020-00001","volume":"5","author":"M Cazzola","year":"2006","unstructured":"Cazzola M. Application of number needed to treat (NNT) as a measure of treatment effect in respiratory medicine. Treat Respir Med. 2006;5:79\u201384.","journal-title":"Treat Respir Med"},{"key":"1078_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1503\/cmaj.080018","volume":"179","author":"SD Aaron","year":"2008","unstructured":"Aaron SD, Fergusson DA. Exaggeration of treatment benefits using the \u201cevent-based\u201d number needed to treat. Can Med Assoc J. 2008;179:669\u201371.","journal-title":"Can Med Assoc J"},{"key":"1078_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/thoraxjnl-2012-202709","volume":"68","author":"S Suissa","year":"2013","unstructured":"Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax. 2013;68:540\u20133.","journal-title":"Thorax"},{"key":"1078_CR31","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","volume":"319","author":"DG Altman","year":"1999","unstructured":"Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492\u20135.","journal-title":"BMJ"},{"key":"1078_CR32","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"DG Altman","year":"1998","unstructured":"Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309\u201312.","journal-title":"BMJ"},{"key":"1078_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v049.i05","volume":"49","author":"BC Wallace","year":"2012","unstructured":"Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational Back-end. J Stat Softw. 2012;49:1\u201315.","journal-title":"J Stat Softw"},{"key":"1078_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth Methods. 2012;3:285\u201399.","journal-title":"Res Synth Methods"},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1111\/j.1532-5415.2007.01373.x","volume":"55","author":"K Tatsumi","year":"2007","unstructured":"Tatsumi K, Fukuchi Y, Group PS. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2007;55:1884\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"1078_CR36","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1532-5415.2005.00592_9.x","volume":"54","author":"H Yasuda","year":"2006","unstructured":"Yasuda H, Yamaya M, Sasaki T, Inoue D, Nakayama K, Tomita N, Yoshida M, Sasaki H. Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2006;54:378\u201380.","journal-title":"J Am Geriatr Soc"},{"key":"1078_CR37","unstructured":"European Commission. A guideline on summary of product characteristics (SmPC). Available at \n                    http:\/\/ec.europa.eu\/health\/\/sites\/health\/files\/files\/eudralex\/vol-2\/c\/smpc_guideline_rev2_en.pdf\n                    \n                  . Accessed June 22, 2017. 2009."},{"key":"1078_CR38","doi-asserted-by":"crossref","unstructured":"Cazzola M, Rogliani P, Calzetta L, Matera MG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52.","DOI":"10.1183\/13993003.01586-2018"},{"key":"1078_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"J Clin Epidemiol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1078-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1078-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1078-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T23:09:46Z","timestamp":1590448186000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1078-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,27]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1078-y","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,27]]},"assertion":[{"value":"16 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PR participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis. Her department was funded by Almirall, Boehringer Ingelheim, Novartis, Zambon and Chiesi Farmaceutici.MGM has participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline and Novartis, and has been a consultant to Chiesi Farmaceutici.CP has acted as a Consultant for Recipharma, ImmunoRegulation, PrEP Biopharma, Ockham Biosciences and Eurodrug. CP also owns equity in Verona Pharma who are developing novel drugs for the treatment of respiratory diseases.EP has no conflict of interest to declare.MC has participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Lallemand, Mundipharma, Novartis, Pfizer, Verona Pharma, and Zambon, and has been a consultant to ABC Farmaceutici, Recipharm, Chiesi Farmaceutici, Lallemand, Novartis, Verona Pharma, and Zambon. His department was funded by Almirall, Boehringer Ingelheim, Novartis, and Zambon.LC has participated as advisor in scientific meetings under the sponsorship of Boehringer Ingelheim and Novartis, received non-financial support by AstraZeneca, received a research grant partially funded by Chiesi Farmaceutici, Boehringer Ingelheim, Novartis, and Almirall, and is or has been a consultant to ABC Farmaceutici, Recipharm, Zambon, Verona Pharma, and Ockham Biotech. His department was funded by Almirall, Boehringer Ingelheim, Novartis, Zambon and Chiesi Farmaceutici.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}